Work

When JAK Selectivity Matters: Worsening Urticaria and Recurrent Allergic Rhinitis After Switching From Baricitinib to Ritlecitinib in Alopecia Areata

Year: 2026

Type: article

Abstract: Dear Editor, Janus kinase (JAK) inhibitors are important treatments for alopecia areata (AA), but differ in kinase selectivity.Baricitinib predominantly inhibits JAK1/2, whereas ritlecitinib selectively inhibits JAK3 and TEC-family kinases [1].However, whether switching between these agents affects concomitant allergic diseases remains unclear.Here, we report recurrent urticaria and allergic rhinitis after switching from baricitinib to ritlecitinib.

Source: The Journal of Dermatology

DOI: 10.1111/1346-8138.70559

Authors: Koki Ito, Yasuaki Ikuno, Masahiro Yamada, Akihiko Yamaguchi, Toshifumi Takahashi, Akiko Arakawa, Noriki Fujimoto

Institutions: Shiga University of Medical Science, Ludwig-Maximilians-Universität München, Leipzig University

Language: English

Topic: Hair Growth and Disorders

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7224669977

FWCI:

Cites: 3

Cited by:

Related to: 10